Results for tag: "Post Transplant Lymphoproliferative Disorder"

Post Transplant Lymphoproliferative Disorder (PTLD) is a rare complication of organ transplantation, caused by an abnormal proliferation of lymphocytes. It is a serious complication of immunosuppressive therapy, which is used to prevent organ rejection. Immunosuppressive drugs are used to reduce the activity of the immune system, allowing the body to accept the transplanted organ. However, these drugs can also increase the risk of PTLD. PTLD is a complex disorder, and treatment depends on the type and severity of the condition. Treatment options include reducing the dose of immunosuppressive drugs, changing the type of immunosuppressive drug, or using chemotherapy or radiation therapy. The PTLD market is driven by the increasing number of organ transplants, the growing prevalence of immunosuppressive drugs, and the increasing awareness of PTLD. Companies in the market include Roche, Novartis, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more